Who Generates Higher Gross Profit? United Therapeutics Corporation or Pharming Group N.V.

Biotech Giants' Gross Profit Battle: United Therapeutics vs. Pharming Group

__timestampPharming Group N.V.United Therapeutics Corporation
Wednesday, January 1, 2014215951651162636000
Thursday, January 1, 201565904271396725000
Friday, January 1, 2016117685421526100000
Sunday, January 1, 2017925870381619600000
Monday, January 1, 20181292038431429100000
Tuesday, January 1, 20191654124471331200000
Wednesday, January 1, 20202030564301375200000
Friday, January 1, 20211696700711563000000
Saturday, January 1, 20221880600001789600000
Sunday, January 1, 20232201040002070000000
Loading chart...

Data in motion

A Tale of Two Biotech Giants: Gross Profit Showdown

In the competitive world of biotechnology, financial performance is a key indicator of success. Over the past decade, United Therapeutics Corporation and Pharming Group N.V. have been vying for dominance in gross profit generation. From 2014 to 2023, United Therapeutics consistently outperformed Pharming Group, boasting a gross profit that was, on average, 12 times higher. In 2023, United Therapeutics reached a peak gross profit of approximately $2.07 billion, while Pharming Group achieved $220 million. This stark contrast highlights United Therapeutics' robust market position and strategic prowess. Despite Pharming Group's impressive growth, with a nearly tenfold increase from 2014 to 2023, it remains a distant second. As the biotech landscape evolves, these financial trends offer a glimpse into the strategic maneuvers and market dynamics shaping the industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025